Newborn Screening Instruments Sales

Newborn Screening Instruments Sales Market Outlook

The global newborn screening instruments market is projected to reach approximately USD 2.5 billion by 2035, exhibiting a robust compound annual growth rate (CAGR) of around 8.4% during the forecast period from 2025 to 2035. The growth of this market is primarily driven by the increasing incidence of congenital disorders, advancements in medical technologies, and the rising awareness among parents regarding newborn health. Furthermore, government initiatives aimed at promoting newborn screening programs are expected to propel the market's development. The rising prevalence of genetic disorders and metabolic diseases among newborns has created a pressing demand for effective screening tools, thus contributing significantly to market growth. Additionally, technological innovations such as the integration of artificial intelligence in screening processes are enhancing the efficiency and accuracy of diagnostic tools.

Growth Factor of the Market

Several key factors are driving the growth of the newborn screening instruments market. First and foremost, the increasing prevalence of newborn diseases, including metabolic and genetic disorders, necessitates the use of advanced screening instruments to ensure early diagnosis and treatment. Additionally, there is a growing trend toward preventive healthcare, with a significant focus on early detection and management of health conditions in neonates. This shift is supported by health authorities and organizations advocating for universal newborn screening programs across various regions. Technological advancements in screening methodologies, such as the development of non-invasive and rapid diagnostic tests, are also enhancing the adoption of these instruments. Furthermore, rising healthcare expenditure, coupled with improvements in healthcare infrastructure, particularly in developing regions, is facilitating wider access to newborn screening services. The drive for innovation in healthcare solutions is leading to the introduction of more sophisticated and efficient screening tools, further fostering market growth.

Key Highlights of the Market

• Rising prevalence of congenital disorders necessitating advanced screening methods.
• Technological advancements improving the efficiency and accuracy of newborn screening.
• Government initiatives promoting universal newborn screening programs.
• Growing awareness among parents about the importance of early diagnosis.
• Increased healthcare expenditure facilitating better healthcare infrastructure for screenings.

By Product Type

Pulse Oximetry :

Pulse oximetry is a non-invasive method widely used in newborn screening to measure the oxygen saturation levels in the blood. This technique is crucial for identifying critical congenital heart defects (CCHDs) in infants, allowing for timely interventions. The rise in awareness regarding the importance of early detection of such defects has spurred the demand for pulse oximeters in hospitals and clinics. Moreover, technological advancements in pulse oximetry devices have led to the introduction of portable and easy-to-use models, enhancing their adoption in various healthcare settings. The growing number of neonatal care units equipped with advanced monitoring systems is expected to further drive the growth of this product segment. The accuracy and reliability of pulse oximetry, coupled with its cost-effectiveness, make it a preferred choice among healthcare providers.

Hearing Screening Devices :

Hearing screening devices are essential for early detection of hearing impairments in newborns, which can otherwise lead to developmental delays if not addressed promptly. The increasing awareness of the significance of auditory health in infants has fueled the growth of this segment. The devices used for hearing screening, such as automated auditory brainstem response (AABR) and otoacoustic emissions (OAE) devices, have seen advancements, making them more efficient and user-friendly. The favorable recommendations by health organizations for universal newborn hearing screening are further propelling the demand for these devices. The rising focus on ensuring comprehensive care for newborns, including hearing assessments, is expected to drive the market for hearing screening devices significantly.

Mass Spectrometers :

Mass spectrometers are vital instruments used in newborn screening to analyze metabolic disorders by detecting biomarkers in blood samples. With the capability to provide a detailed analysis of various substances in a single test, mass spectrometry has become a cornerstone in neonatal diagnostics. The growing prevalence of inherited metabolic disorders has led to an increased demand for mass spectrometry techniques. Advances in technology have improved the sensitivity and specificity of these instruments, enabling earlier and more accurate diagnoses. The integration of mass spectrometry in newborn screening programs is also being supported by government initiatives aimed at enhancing early detection capabilities, making it a critical product type in the market.

DNA Assays :

DNA assays play a crucial role in the identification of genetic disorders in newborns. These assays allow for the detection of specific genetic mutations and conditions, facilitating early intervention and management. The increasing prevalence of genetic disorders, along with advancements in genotyping technologies, has spurred demand for DNA-based screening methods. The market for DNA assays is bolstered by the growing acceptance of genetic testing among parents and healthcare providers. Furthermore, the development of next-generation sequencing technologies is enhancing the accuracy and efficiency of DNA assays, driving their adoption in newborn screening programs. As awareness of the importance of genetic health continues to rise, the need for reliable DNA assays is expected to grow significantly.

Others :

The "Others" category encompasses various newborn screening instruments not classified under the main product types. This includes devices and tools that may facilitate additional testing and screening processes, such as analyzers for specific biomarkers and advanced imaging systems. The growth in this segment is largely attributed to the diversification of screening methodologies and the need for comprehensive testing solutions. Innovations in this space are fostering the development of more versatile instruments capable of accommodating a broader range of tests. The increasing focus on personalized medicine and targeted screening in newborn care is propelling the demand for these miscellaneous instruments, thus contributing to the overall market growth.

By Application

Hospitals :

Hospitals represent a significant application segment for newborn screening instruments, primarily due to their central role in the healthcare continuum. The necessity for immediate and accurate screening upon birth drives the adoption of various screening devices within hospital settings. Hospitals are equipped with advanced facilities and trained personnel capable of conducting comprehensive newborn screenings, ensuring timely interventions for identified conditions. The trend towards establishing specialized neonatal units within hospitals has further increased the demand for these screening instruments. Additionally, government regulations and guidelines mandating newborn screenings in hospitals are propelling the growth of this application segment. The rise in patient inflow and the need for enhanced neonatal care solutions are expected to significantly boost the hospital application segment of the market.

Clinics :

Clinics serve as vital points of care for newborns, with many parents opting for specialized pediatric clinics for screenings. The increasing preference for outpatient care and the growing number of pediatric clinics are fostering the demand for newborn screening instruments in this segment. Clinics often provide a more personalized approach to healthcare, which is appealing to parents seeking comprehensive care for their infants. The availability of portable and user-friendly screening instruments has made it feasible for clinics to conduct newborn screenings efficiently. As awareness regarding the significance of early detection continues to grow, the role of clinics in providing accessible screening services is becoming increasingly important, subsequently driving growth in this application area.

Diagnostic Centers :

Diagnostic centers are crucial for providing specialized testing services, including newborn screenings, where advanced diagnostic technologies are utilized. The rise in the number of diagnostic centers offering comprehensive screening packages has increased the demand for newborn screening instruments. These centers are often equipped with state-of-the-art technology, allowing for timely and accurate diagnoses of metabolic and genetic disorders. The increasing focus on preventive healthcare and early detection is encouraging more parents to utilize diagnostic centers for newborn screenings. Moreover, partnerships between hospitals and diagnostic centers are facilitating the seamless transfer of infants for advanced testing, further boosting the market for newborn screening instruments within this application segment.

Research Institutes :

Research institutes play a pivotal role in developing and validating new newborn screening methodologies and technologies. These institutions are often at the forefront of innovations in diagnostic tools and screening techniques, contributing to the broader understanding of congenital and genetic disorders. As research into newborn health continues to expand, the demand for specialized screening instruments within research settings is anticipated to grow. Collaborations between research institutes and healthcare providers are fostering the advancement of screening protocols, driving the need for state-of-the-art instruments. The increasing focus on precision medicine and the characterization of rare genetic disorders will further enhance the role of research institutes in the newborn screening instruments market.

By Distribution Channel

Direct Sales :

Direct sales channels have emerged as a primary mode for distributing newborn screening instruments, allowing manufacturers to establish direct connections with healthcare providers. This approach enables companies to provide personalized services and support to hospitals and clinics, thereby enhancing customer satisfaction. Direct sales facilitate better product training, ensuring that healthcare professionals are well-informed about the equipment's use and maintenance. Additionally, manufacturers can tailor their offerings based on the specific needs of healthcare providers, fostering stronger relationships and boosting sales. The growing emphasis on improving patient outcomes through better screening practices is driving the preference for direct sales channels in the newborn screening instruments market.

Distributor Sales :

Distributor sales are a prominent distribution channel within the newborn screening instruments market, providing manufacturers with a broad reach across various healthcare facilities. Distributors often have established networks and relationships with clinics, hospitals, and diagnostic centers, facilitating the efficient delivery of screening instruments. This channel is particularly beneficial for manufacturers looking to penetrate new markets or regions where they may lack direct presence. The relationship between manufacturers and distributors can enhance product visibility and accessibility, ultimately driving sales growth. The reliance on distributors is also advantageous for healthcare providers, as they can source a range of newborn screening instruments from a single supplier, simplifying the procurement process.

By Technology Type

Tandem Mass Spectrometry :

Tandem mass spectrometry (TMS) is a sophisticated analytical technique widely used in newborn screening to detect various metabolic disorders. This technology enables the simultaneous analysis of multiple biomarkers in a single sample, enhancing the efficiency of the screening process. The growing prevalence of inherited metabolic conditions necessitates the use of sensitive and specific detection methods like TMS. Advances in TMS technology have improved its accuracy and yield, making it a preferred choice in newborn screening programs. The ability to provide comprehensive metabolic profiling has led to its increased adoption in hospitals and diagnostic centers, driving the growth of this segment significantly.

Enzyme Assays :

Enzyme assays are critical tools used to assess enzymatic activities in newborns, facilitating the early diagnosis of various metabolic disorders. These assays are essential for detecting conditions such as phenylketonuria (PKU) and galactosemia, which require immediate treatment to prevent long-term complications. The simplicity and cost-effectiveness of enzyme assays make them an attractive option for many healthcare providers. Furthermore, advancements in assay technologies have enhanced their sensitivity and specificity, promoting their wider use in newborn screening programs. The increasing awareness of metabolic diseases among healthcare professionals and parents is further driving the demand for enzyme assays in the market.

DNA-Based Assays :

DNA-based assays are increasingly utilized in newborn screening to detect genetic disorders by analyzing specific genetic mutations. These assays provide a powerful tool for identifying conditions that may not be detectable through traditional screening methods. The growing acceptance of genetic testing among parents and healthcare providers is contributing to the expansion of this technology segment. Moreover, advancements in next-generation sequencing technologies are improving the accuracy and efficiency of DNA assays, allowing for more comprehensive screening. The heightened focus on understanding the genetic basis of disorders is propelling the demand for DNA-based assays in newborn screening programs worldwide.

Electrophoresis :

Electrophoresis is a laboratory technique used to separate macromolecules like DNA, RNA, or proteins based on their size and charge. In newborn screening, electrophoresis is utilized for the analysis of hemoglobinopathies and metabolic disorders. The accuracy and reliability of electrophoresis make it an essential technique for comprehensive newborn screening. With the growing emphasis on early diagnosis and intervention, the adoption of electrophoresis in various healthcare settings is expected to increase. Furthermore, continuous improvements in electrophoretic techniques are enhancing their effectiveness, leading to a broader application of this technology in the newborn screening market.

By Region

The North American region holds a prominent position in the newborn screening instruments market, accounting for nearly 40% of the global market share in 2023. This dominance is attributed to the well-established healthcare infrastructure, increasing prevalence of congenital disorders, and proactive government initiatives for universal newborn screening programs. The region has witnessed significant advancements in medical technology, further driving the demand for sophisticated newborn screening instruments. Additionally, the region's focus on research and development contributes to continuous innovations in screening methodologies. The CAGR for the North American market is projected to be around 8.6%, reflecting the region's ongoing commitment to improving newborn health outcomes.

Europe is another significant market for newborn screening instruments, capturing approximately 30% of the global market share in 2023. The region has implemented comprehensive newborn screening programs, leading to increased awareness about the importance of early detection of congenital disorders. Countries such as Germany and the UK are actively investing in healthcare infrastructure and innovative technologies for newborn screening. The rising awareness among parents regarding genetic disorders and metabolic diseases is driving the demand for various screening instruments. The European newborn screening instruments market is expected to grow at a CAGR of 7.8%, reflecting a sustained commitment to enhancing neonatal healthcare services across the region.

Opportunities

The newborn screening instruments market presents numerous opportunities for growth and innovation. Firstly, the expansion of healthcare infrastructure in developing regions is opening new avenues for the adoption of advanced screening technologies. As more hospitals and clinics emerge in these regions, the demand for reliable newborn screening instruments is expected to increase significantly. Additionally, there is an opportunity for manufacturers to collaborate with governments and healthcare organizations to promote awareness of the importance of newborn screening programs, thus expanding their reach. The rising trend of personalized medicine and genetic screening also presents a unique opportunity for companies to develop targeted screening solutions that cater to specific genetic disorders prevalent in various populations. Furthermore, as technology continues to evolve, integrating artificial intelligence and machine learning into screening processes can enhance diagnostic accuracy, presenting a substantial opportunity for innovation in the market.

Another key opportunity lies in the development of point-of-care testing (POCT) devices that enable immediate screening and diagnosis of newborn conditions at the bedside. This advancement would significantly improve patient outcomes by facilitating timely interventions. Additionally, there is a growing interest in expanding newborn screening programs to include a broader range of conditions, requiring innovative instruments capable of comprehensive testing. The focus on maternal and child health, driven by various global health initiatives, further supports the growth trajectory of the newborn screening instruments market. Furthermore, advancements in telemedicine and remote monitoring present opportunities for enhancing access to screening services, especially in rural and underserved areas, ultimately contributing to improved neonatal health outcomes.

Threats

Despite the promising growth prospects, the newborn screening instruments market faces several threats that could impede its progress. One significant challenge is the stringent regulatory requirements and approval processes for diagnostic devices, which can slow down the introduction of new products into the market. Manufacturers must navigate complex regulatory landscapes, which may vary significantly across regions, increasing the time and costs associated with product development and commercialization. Furthermore, the high cost of advanced screening technologies can be a barrier for healthcare facilities, particularly in developing regions with limited budgets. This discrepancy in access to advanced screening tools may lead to disparities in newborn care and outcomes, posing a risk to the market's growth. Additionally, the competition from alternative diagnostic methods could threaten the adoption of certain newborn screening instruments, impacting sales and market share.

Moreover, there is the potential threat of market saturation as more players enter the newborn screening instruments market, leading to increased competition and price sensitivity. Companies may be compelled to lower their prices to maintain market share, adversely affecting profit margins. There is also an ongoing risk of technological obsolescence as rapid advancements in medical technology can quickly render existing products outdated. Manufacturers must continuously invest in research and development to stay ahead of emerging trends and innovations. Lastly, the ongoing global challenges such as pandemics and health crises can disrupt supply chains and affect the distribution of newborn screening instruments, posing additional threats to the market's stability and growth.

Competitor Outlook

• Graham Medical
• Natus Medical Incorporated
• PerkinElmer, Inc.
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Roche Diagnostics
• Ortho Clinical Diagnostics
• Medtronic plc
• Newborn Screening Solutions, LLC
• Hologic, Inc.
• Quest Diagnostics
• Siemens Healthineers
• Fisher Scientific

The competitive landscape of the newborn screening instruments market is characterized by a mix of established players as well as emerging companies striving for market share. Key manufacturers are heavily investing in research and development to introduce innovative products that enhance the accuracy and efficiency of newborn screenings. Collaborative partnerships between healthcare providers and manufacturers are also gaining momentum, creating synergies that drive product development and improve service delivery. The market is increasingly focused on enhancing technology, leading to advancements such as point-of-care testing and integration of artificial intelligence in screening processes. This competitive dynamic fosters an environment of continuous improvement, ensuring that healthcare providers have access to the latest screening technologies.

The leading players in the newborn screening instruments market include PerkinElmer, Natus Medical, and Abbott Laboratories, each holding substantial market shares due to their extensive portfolios of screening devices and technologies. PerkinElmer is renowned for its pioneering work in early detection and newborn screening solutions, offering a range of advanced screening methodologies such as tandem mass spectrometry and DNA assays. Natus Medical is recognized for its comprehensive range of neonatal products, including hearing screening devices and pulse oximetry instruments. Abbott Laboratories stands out with its innovative diagnostic solutions tailored for newborn health, consistently focusing on enhancing screening accuracy and efficiency. These companies leverage their strong research capabilities, broad distribution networks, and established relationships with healthcare providers to maintain their competitive edge in the market.

Emerging players are also making significant strides in the newborn screening instruments market, often focusing on niche segments or offering specialized products. Companies such as Newborn Screening Solutions and Hologic, Inc. are dedicated to developing targeted screening tools that address specific needs in the market. The competitive dynamics are further influenced by the increasing trend of mergers and acquisitions, as established players seek to expand their technological capabilities and market reach by acquiring innovative startups. As competition intensifies, companies are also focusing on enhancing customer engagement through educational initiatives, promoting the benefits of early detection and screening to healthcare providers and parents alike. Overall, the newborn screening instruments market is poised for growth driven by both established leaders and innovative newcomers, fostering an ecosystem of continuous advancement in newborn health solutions.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Hologic, Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Medtronic plc
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Graham Medical
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Fisher Scientific
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 PerkinElmer, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Quest Diagnostics
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Diagnostics
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Abbott Laboratories
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Siemens Healthineers
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Agilent Technologies, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Bio-Rad Laboratories, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Natus Medical Incorporated
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Ortho Clinical Diagnostics
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Thermo Fisher Scientific Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Newborn Screening Solutions, LLC
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Newborn Screening Instruments Sales Market, By Application
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Diagnostic Centers
    • 6.1.4 Research Institutes
  • 6.2 Newborn Screening Instruments Sales Market, By Product Type
    • 6.2.1 Pulse Oximetry
    • 6.2.2 Hearing Screening Devices
    • 6.2.3 Mass Spectrometers
    • 6.2.4 DNA Assays
    • 6.2.5 Others
  • 6.3 Newborn Screening Instruments Sales Market, By Technology Type
    • 6.3.1 Tandem Mass Spectrometry
    • 6.3.2 Enzyme Assays
    • 6.3.3 DNA-Based Assays
    • 6.3.4 Electrophoresis
  • 6.4 Newborn Screening Instruments Sales Market, By Distribution Channel
    • 6.4.1 Direct Sales
    • 6.4.2 Distributor Sales

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Newborn Screening Instruments Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Newborn Screening Instruments Sales market is categorized based on

By Product Type

• Pulse Oximetry
• Hearing Screening Devices
• Mass Spectrometers
• DNA Assays
• Others

By Application

• Hospitals
• Clinics
• Diagnostic Centers
• Research Institutes

By Distribution Channel

• Direct Sales
• Distributor Sales

By Technology Type

• Tandem Mass Spectrometry
• Enzyme Assays
• DNA-Based Assays
• Electrophoresis

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Graham Medical
• Natus Medical Incorporated
• PerkinElmer, Inc.
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Roche Diagnostics
• Ortho Clinical Diagnostics
• Medtronic plc
• Newborn Screening Solutions, LLC
• Hologic, Inc.
• Quest Diagnostics
• Siemens Healthineers
• Fisher Scientific